N-Cbz-4-哌啶乙酸乙酯 | 80221-26-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-Cbz-4-哌啶乙酸乙酯
• 中文别名: N-CBZ-4-哌啶乙酸乙酯
• 英文名称: benzyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate
• CAS: 80221-26-7
• 化学式: C₁₇H₂₃NO₄
• mdl: MFCD09953323
• 分子量: 305.374
• InChiKey: SULSTAOSZUXHPL-UHFFFAOYSA-N

物化性质

• 沸点：
  416.1±28.0 °C(Predicted)
• 密度：
  1.131±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.529
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  2-8℃

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl n-cbz-4-piperidineacetate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl n-cbz-4-piperidineacetate
CAS number: 80221-26-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C17H23NO4
Molecular weight: 305.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-Cbz-4-哌啶乙酸乙酯 在 三乙基硼氢化锂 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 1-CBZ-4-哌啶乙醛
  参考文献：
  名称：

  [EN] N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE
  [FR] DÉRIVÉS DE N-ARYLE ET DE N-HÉTÉROARYLE PIPÉRIDINE EN TANT QU'AGONISTES DES RÉCEPTEURS HÉPATIQUES X, COMPOSITIONS ET LEUR UTILISATION

  摘要：

  提供的是某些取代的N-芳基和N-杂芳基哌啶化合物，其化学式为(I)以及药用可接受的盐，其中R1、R2、R3、L、R4、L1、Q、R5和R6定义如所述。所述新颖化合物，以及包含其化合物的药用可接受组合物，可能用作肝X-β受体(LXRβ)激动剂，并可用于治疗或预防与之相关的病理学。这类病理学包括但不限于炎症性疾病和以胆固醇和脂质代谢缺陷为特征的疾病，例如阿尔茨海默病。

  公开号：

  WO2018068297A1
• 作为产物：
  描述：

  4-羟基-1-哌啶甲酸苄酯 在 palladium on activated charcoal 、 乙二胺 氢气 、 silica gel 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 20.0 ℃ 、506.62 kPa 条件下， 反应 50.0h， 生成 N-Cbz-4-哌啶乙酸乙酯
  参考文献：
  名称：

  Pd/C(en)-Catalyzed Chemoselective Hydrogenation with Retention of the N-Cbz Protective Group and its Scope and Limitations

  摘要：

  A chemoselective method for the hydrogenation of acetylene, olefin, azide, nitro and benzyl ester functionalities with retention of the aliphatic N-Cbz group was established. The chemoselectivity was accomplished by using a combination of 5% Pd/C-ethylenediamine [5% Pd/C(en)] and THF (or 1,4-dioxane) as a solvent, and the scope and limitations of this methodology were investigated. These results reinforce the utility of N-Cbz protective groups in synthetic chemistry, especially in peptide synthesis (C) 2000 Elsevier Science Ltd. All lights reserved.

  DOI：

  10.1016/s0040-4020(00)00771-7

文献信息

• [EN] PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] DÉRIVÉS D'ACIDE PYRIDIN-3-YLE ACÉTIQUE UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：VIIV HEALTHCARE UK NO 5 LTD

  公开号：WO2018127801A1

  公开（公告）日：2018-07-12

  Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.

  公开了式I化合物，包括药学上可接受的盐、包含这些化合物的药物组合物、制备这些化合物的方法以及它们在抑制HIV整合酶和治疗HIV或AIDS感染者中的用途。
• Cgrp Receptor Antagonists
  申请人：Burgey S. Christopher

  公开号：US20070287696A1

  公开（公告）日：2007-12-13

  Compounds of Formula I: and Formula II: (where variables R 1 , R 2 , R 3 , R 4 , A, B, D, G, J, Q, T, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, pharmaceutical compositions comprising these compounds, use of these compounds and compositions to prevent or treat diseases involving CGRP.

  化合物的化学式I：和化学式II：（其中变量R1、R2、R3、R4、A、B、D、G、J、Q、T、W、X和Y的定义如下）可作为CGRP受体拮抗剂，在涉及CGRP的疾病的治疗或预防中有用，包括这些化合物的药物组合物、使用这些化合物和组合物来预防或治疗涉及CGRP的疾病。
• SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS
  申请人：DeMong E. Duane

  公开号：US20070197590A1

  公开（公告）日：2007-08-23

  Substituted dipiperidine compounds of Formula (I) or a form thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.

  Formula (I)中的取代二哌啶化合物或其形式，它们是CCR2拮抗剂，可用于预防、治疗或改善需要的主体中的CCR2介导的炎症综合征、紊乱或疾病。
• [EN] PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS DE PIPÉRIDINE EN TANT QU'AGONISTES DES RÉCEPTEURS BÊTA X DU FOIE, COMPOSITIONS ET UTILISATION ASSOCIÉES
  申请人：MERCK SHARP & DOHME

  公开号：WO2018068296A1

  公开（公告）日：2018-04-19

  Piperidine compounds of the Formular: (I) and pharmaceutically acceptable salts thereof, wherein X, Y, R 1, R 2, R 3, L, R 4, L 1, Q and R 5 are as defined herein. The compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

  吡啶类化合物的化学式：(I)及其药用可接受盐，其中X、Y、R1、R2、R3、L、R4、L1、Q和R5的定义如本文所述。这些化合物及包含其化合物的药用可接受组合物可用作肝X-β受体（LXRβ）激动剂，可能用于治疗或预防与之相关的病理。这些病理包括但不限于炎症性疾病和胆固醇和脂质代谢缺陷所特征的疾病，例如阿尔茨海默病。
• [EN] ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS D'ETHER D'ARYL ET D'HETEROARYLE EN TANT QU'AGONISTES DES RÉCEPTEURS Β X DU FOIE, COMPOSITIONS ET UTILISATION ASSOCIÉE
  申请人：MERCK SHARP & DOHME

  公开号：WO2018068295A1

  公开（公告）日：2018-04-19

  Substituted aryl and heteroaryl ether compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R 1, R 2, R 3, L, R 4, L 1, Q, and R 5 are as defined herein. These compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

  式(I)中的取代芳基和杂环芳基醚化合物及其药用盐，其中X、R1、R2、R3、L、R4、L1、Q和R5如本文所定义。这些化合物和含有其化合物的药用组合物可用作肝X-β受体(LXRβ)激动剂，并可能用于治疗或预防与之相关的病理。这些病理包括但不限于炎症性疾病和以胆固醇和脂质代谢缺陷为特征的疾病，如阿尔茨海默病。